Recent news on Factive

FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five ...  -  May 2, 2007
PipelineReview.com (press release),Oscient first launched FACTIVE for the seven-day treatment of CAP and the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB)

Oscillating Oscient  -  May 7, 2007
Motley FoolRecent developments include a convertible debt offering in April, additional FDA approval for currently marketed antibiotic Factive for the five-day

FDA OKs shorter course for Oscient's drug  -  May 2, 2007
United Press InternationalFactive, which was previously approved for a seven-day regimen for treating community-acquired pneumonia, or CAP, is now approved for a five-day course to

Oscient Pharmaceuticals (OSCI) Misses Q1 EPS by 12c, Receives FDA ...  -  May 2, 2007
StreetInsider.com (subscription),Separately, The US Food and Drug Administration (FDA) has approved Oscient Pharmaceuticals' FACTIVE tablets for the five-day treatment of community-acquired

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  -  Apr 27, 2007
American Digital Networks (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Targanta Seeks $86M In IPO For Antibiotic Development  -  May 14, 2007
BioWorld Online,...s Factive (gemifloxacin) in acute bacterial sinusitis. (See BioWorld Today, Sept. 13, 2006, and Oct. 24, 2006.) Whether or not cSSSI proves to be an

Oscient Pharmaceuticals Announces Successful Convertible Debt ...  -  26 Apr 2007
Business Wire (press release),FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient Pharmaceuticals Announces Increase in Offering Size of New ...  -  Apr 18, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient predicts bullish earnings  -  Apr 11, 2007
Boston Globe,Oscient said about $12 million will come from Antara, and about $11 million will come from the pneumonia and bronchitis treatment Factive.

Oscient Pharma Expects Q1 Revenue Of $23 Mln - Update  -  Apr 11, 2007
Trading Markets,During the first quarter, about 99000 revenue generating prescriptions for FACTIVE were dispensed. In the first quarter of 2006, 118000 prescriptions were

Oscient Pharma Issues Preliminary Q1 Revenue Results - Quick Facts  -  Apr 11, 2007
Trading Markets,The company noted that the results for the latest quarter are expected to include $12 million from Antara, and $11 million from Factive tablets.

Med Ad News Honors Health-Care Advertisers at 18th Annual Manny Awards  -  Apr 18, 2007
PharmaLive.com (press release),...s anti-infective Factive by engaging professional with a customized version of the popular, addictive game sudoku. Ignite Health was awarded the Manny for

ANA380 Exhibits Activity In Vitro Against Multiple Clinically ...  -  Apr 16, 2007
Drug Newswire (press release),LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in

LG Life Sciences and Takeda Announce Collaboration for Anti ...  -  Mar 30, 2007
PharmaLive.com (press release),LGLS seeks to continue developing global brand products such as Factive® (gemifloxacin) and expanding its marketing presence in the world with focus in Asia

Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in ...  -  Mar 2, 2007
CNW Telbec (Communiqués de presse),Oscient granted the commercialization rights for FACTIVE to Abbott Canada in August of last year. "As the most active member of the fluoroquinolone class of

Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in ...  -  Mar 2, 2007
Genetic Engineering News (press release),..."As the most active member of the fluoroquinolone class of antibiotics in vitro, FACTIVE is an important addition to our anti-infective product portfolio,"

Abbott launches Factive in Canada  -  Mar 2, 2007
United Press InternationalOscient, which owns Factive, granted the commercialization rights to Abbott's Canadian affiliate, Abbott Canada, last year. Oscient received a milestone

Oscient expands Factive to Canada  -  Mar 2, 2007
Boston Globe,The Waltham drug maker said today Abbott Canada, an affiliate of Abbott Inc., are now selling the firm's Factive tablets, a five-day treatment for acute

Oscient Pharmaceuticals Reports Financial Results for Fourth ...  -  Feb 27, 2007
Business Wire (press release),...“During 2006 we also made significant strides toward building FACTIVE into a global brand by granting commercialization rights to FACTIVE in our licensed

Oscient Pharmaceuticals Files Registration Statements for Proposed ...  -  Mar 15, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

CORRECTED: Webcast Alert: Oscient Pharmaceuticals to Present at ...  -  Mar 8, 2007
PharmaLive.com (press release),The Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent Canadian launch of FACTIVE(R)

Oscient sounds out notes with SEC  -  Mar 15, 2007
Boston Globe,The Waltham company markets such drugs as Antara, used to treat high cholesterol, and Factive, used in treatment of chronic bronchitis.

Williams-Labadie Promotes Susan Choudhry to Senior Account Supervisor  -  Mar 14, 2007
PharmaLive.com (press release),Choudhry started at Williams-Labadie in 2003 as an Account Executive and she has worked on a number of accounts, including FACTIVE® (Oscient

Market Report -- In Play (WIRES)  -  Mar 2, 2007
MSN MoneyOn The Wires Abbott Canada has launched Oscient Pharmaceuticals Corp's (OSCI) fluoroquinolone antibiotic, FACTIVE tablets in Canada for the five-day

UPDATE 1-Oscient Pharma narrows 4th-qtr loss, shares jump  -  Feb 27, 2007
Reuters...$18.3 million as the company recorded $12.5 million from the sales of Antara and $5.5 million from its antibiotic Factive, Oscient said in a statement.

Oscient Pharmaceuticals "strong buy," target price reduced  -  Feb 28, 2007
newratings.comWhile Factive sales were adversely impacted by a mild early winter, sales are likely to be picking up on account of the severe weather in early 2007,

New Treatment Guidelines for Community-Acquired Pneumonia ...  -  Feb 22, 2007
PharmaLive.com (press release),..."This official statement of both the IDSA and ATS further illustrates an important role for FACTIVE, the most potent fluoroquinolone in vitro,

Market Report -- In Play (OSCI)  -  Feb 22, 2007
MSN MoneyOscient Pharma says new treatment guidelines for community-acquired pneumonia highlight utility of Factive tablets Co announces it's Factive tablets,

Oscient Pharmaceuticals Announces Date for Release of Fourth ...  -  Feb 15, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Biotech Stocks Day-In-Review: Amgen Drags Biotech Lower  -  Jan 28, 2007
Seeking Alpha,Oscient Pharma (OSCI) completed enrollment in a post-approval trial of Factive, its fluoroquinolone antibiotic. Following approval in late 2004,

Oscient Pharmaceuticals and Menarini Group Enter into European ...  -  Jan 5, 2007
PipelineReview.com (press release),..."With this agreement, we have successfully granted FACTIVE commercialization rights in all of our licensed territories to leading pharmaceutical companies

Oscient Pharmaceuticals Amends Factive License Agreement with LG ...  -  Dec 29, 2006
PharmaLive.com (press release),In addition, the amendment restructures the economic terms relating to sales of FACTIVE in Europe, including a reduction in royalty rates on future sales to

Oscient shares soar on Factive licensing pact amendment  -  Dec 29, 2006
ReutersO: Quote, Profile , Research) said it amended a license agreement with LG Life Sciences Ltd. for the Factive antibiotic to include more European countries,

Oscient, LG Life Sci. expand Factive pact  -  Dec 29, 2006
United Press International29 (UPI) -- US firm Oscient Pharmaceuticals said Friday it has amended its Factive License Agreement with LG Life Sciences. Specifically, the company said

Oscient Amends Factive Contract  -  Dec 29, 2006
Houston Chronicle,Oscient Pharmaceuticals Corp. said Friday it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to include several European countries

Oscient shares soar on Factive licensing pact amendment  -  Dec 29, 2006
Therapeutics Daily (subscription) (press release),BANGALORE (Reuters) - Oscient Pharmaceuticals Corp. said it amended a license agreement with LG Life Sciences Ltd. for the Factive antibiotic to include

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Jan 8, 2007
PharmaLive.com (press release),In 2006, approximately $22 million in revenue was derived from FACTIVE, approximately $17 million in revenue from ANTARA, which was part of the Company's

Oscient expects 2007 revenue to rise 80%  -  Jan 8, 2007
Boston Globe,The 2006 estimate includes about $22 million in revenue from Factive, about $17 million in revenue from Antara, and about $7 million in revenue from

News from Oscient Pharmaceuticals highlights the most recent ...  -  Jan 11, 2007
Therapeutics Daily (subscription) (press release),...outcome of short-course treatment with Factive (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (OSCI) lead antibiotic product,

Oscient soars on amended licensing deal  -  Dec 29, 2006
MarketWatchOscient also said the companies have lowered the royalty rate on future sales of Factive in order to attract a commercial partner in Europe.

Market Report -- In Play (OSCI)  -  Dec 29, 2006
MSN MoneyOscient Pharma amends Factive license agreement with LG Life Sciences Co announces it has amended its license and option agreement with LG Life Sciences for

Oscient Pharma sees fourth-quarter revenue at $18 mln  -  Jan 8, 2007
ReutersThe company said it expects $12 million from its cardiovascular product Antara, and about $6 million from Factive, an antibiotic for chronic bronchitis and

Friday's Health Winners & Losers  -  Dec 29, 2006
TheStreet.comFactive antibiotic product license to LG Life Sciences and that LG is now authorized to sell Factive in all 40 member countries of the European Union.

Friday's Small-Cap Winners & Losers  -  Dec 29, 2006
TheStreet.comOscient Pharmaceuticals (OSCI - commentary - Cramer's Take) rocketed more than 36% on news that it will pay lower royalties in connection with its Factive

BIOTECH STOCKS Drug stocks move lower, Oscient rockets  -  Dec 29, 2006
MarketWatchThe company said it has amended its license and option agreement for Factive with LG Life Sciences to include all nations of the European Union.

Pharma Sector: Few Newsmakers Of The Week - Eli Lilly, Bristol ...  -  Dec 29, 2006
Trading Markets,The amendment provides for the inclusion of 40 European countries and restructures the economic terms relating to sales of Factive in Europe.

Apple Among Big Movers on Wall Street  -  Dec 29, 2006
Forbes,The drug maker said it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to include several European countries - including France,

Volume Spikes: OSCI ZICA FORG BCON  -  Dec 29, 2006
Houston Chronicle,Oscient Pharmaceuticals Corp. traded more than usual after it said it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to include

Volume Spikes: OSCI ZICA FORG BCON  -  Dec 29, 2006
Houston Chronicle,Oscient Pharmaceuticals Corp. traded more than usual after the company said it amended a contract for its Factive antibiotic with LG Life Sciences Ltd. to

Biotech Stocks Day-in-Review: BioCryst Gets Flu Drug Support  -  Jan 5, 2007
Seeking Alpha,Oscient Pharma (OSCI) sold the European marketing rights for Factive, its antibiotic, to Menarini, an Italian company with over $3 billion of revenue last

Stocks to Watch, Jan.3: AngioDynamics, Apple  -  Jan 2, 2007
FOX News...(OSCI) jumped 20 percent on news that it has amended its licensing deal in Europe for its antibiotic Factive. McAfee Inc. (MFE) said it will amend certain

FDA Accepts as ``Complete Response'' Oscient Pharmaceuticals ...  -  Nov 28, 2006
PipelineReview.com (press release),FACTIVE is currently approved by the FDA for the five-day treatment of acute exacerbations of chronic bronchitis (AECB) and the seven-day treatment of CAP.

Oscient Factive FDA Response Complete  -  Nov 27, 2006
Forbes,The company is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days. The treatment is already approved as a

Oscient Factive FDA response complete  -  Nov 27, 2006
Boston Globe,The company, which is based in Waltham, is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days.

Oscient Factive FDA response complete  -  Nov 27, 2006
Eyewitness News,The Waltham-based biotech drugmaker is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days.

Oscient Pharmaceuticals Provides Financial Projections for Fiscal ...  -  Dec 8, 2006
PharmaLive.com (press release),..."While ANTARA has become our top selling product, we also remain focused on growing FACTIVE prescriptions during the respiratory tract infection season."

Oscient Pharmaceuticals to Present at 25th Annual JPMorgan ...  -  Dec 19, 2006
Genetic Engineering News (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

FDA accepts Oscient pneumonia drug submission  -  Nov 27, 2006
Pharmaceutical Business ReviewThe FDA has accepted Oscient Pharmaceuticals' amended application for Factive tablets for the five-day treatment of community-acquired pneumonia,

Market Report -- In Play (OSCI)  -  Nov 27, 2006
MSN MoneyOscient Pharma (OSCID) says FDA accepts as "Complete Response'' OSCI's submission following Factive approvable letter for 5-day CAP OSCID says the FDA has

Officials from Oscient Pharmaceuticals provide details of new ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),...outcome of short-course treatment with Factive (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (OSCI) lead antibiotic product,

Oscient says FDA accepts application  -  Nov 27, 2006
ReutersThe US Food and Drug Administration had asked for clarification and more interpretation of certain data included in its application for Factive as a

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,Oscient Pharma is seeking approval of Factive for the five-day treatment of community-acquired pneumonia or CAP of mild to moderate severity.

Oscient Pharmaceuticals Provides Financial Projections for Fiscal ...  -  Dec 8, 2006
PharmaLive.com (press release),..."While ANTARA has become our top selling product, we also remain focused on growing FACTIVE prescriptions during the respiratory tract infection season."

FDA Accepts as ``Complete Response'' Oscient Pharmaceuticals ...  -  Nov 28, 2006
PipelineReview.com (press release),FACTIVE is currently approved by the FDA for the five-day treatment of acute exacerbations of chronic bronchitis (AECB) and the seven-day treatment of CAP.

Oscient Factive FDA Response Complete  -  Nov 27, 2006
Forbes,The company is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days. The treatment is already approved as a

Oscient Factive FDA response complete  -  Nov 27, 2006
Boston Globe,The company, which is based in Waltham, is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days.

Oscient Factive FDA response complete  -  Nov 27, 2006
Eyewitness News,The Waltham-based biotech drugmaker is trying to get approval for Factive to treat community-acquired pneumonia, or CAP, over five days.

Officials from Oscient Pharmaceuticals provide details of new ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),...outcome of short-course treatment with Factive (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (OSCI) lead antibiotic product,

Reverse Split of Oscient Pharmaceuticals Stock to Be Effected with ...  -  Nov 16, 2006
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

FDA accepts Oscient pneumonia drug submission  -  Nov 27, 2006
Pharmaceutical Business ReviewThe FDA has accepted Oscient Pharmaceuticals' amended application for Factive tablets for the five-day treatment of community-acquired pneumonia,

Market Report -- In Play (OSCI)  -  Nov 27, 2006
MSN MoneyOscient Pharma (OSCID) says FDA accepts as "Complete Response'' OSCI's submission following Factive approvable letter for 5-day CAP OSCID says the FDA has

Oscient says FDA accepts application  -  Nov 27, 2006
ReutersThe US Food and Drug Administration had asked for clarification and more interpretation of certain data included in its application for Factive as a

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,Oscient Pharma is seeking approval of Factive for the five-day treatment of community-acquired pneumonia or CAP of mild to moderate severity.

FDA to Review Oscient's Factive Drug  Jun 28, 2006
...after announcing a Food and Drug Administration advisory committee will review the biotech drug maker's application to sell its infection drug Factive as a ... -Houston Chronicle

Factive To Get Committee Review Sept. 12 For Acute Bacterial ...  Jun 28, 2006
FDA’s Anti-Infective Drugs Advisory Committee will review Oscient’s sNDA for the antibiotic Factive (gemifloxacin) Sept. 12 ... -FDA Advisory Committee

Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory ...  Jun 28, 2006
Nasdaq: OSCI) that the FDA's Anti-Infective Drugs Advisory Committee will review the supplemental New Drug Application (sNDA) for FACTIVE(R) (gemifloxacin ... -Business Wire

Oscient Pharma (OSCI) Says FDA Committee will Review sNDA for ...  Jun 28, 2006
Nasdaq: OSCI) that the FDA's Anti-Infective Drugs Advisory Committee will review the supplemental New Drug Application (sNDA) for FACTIVE tablets for the ... -StreetInsider.com (subscription)

Oscient Pharma says FDA panel to review sinusitis treatment  Jun 28, 2006
...acute bacterial sinusitis. The review of the Factive drug by the FDA's Anti-Infective Drugs Advisory Committee on Sept. 12 comes ... -Reuters

Pandemic virus preparations in planning for city  Jul 4, 2006
..."I want to make it very clear that people should not panic," said Khan. "There is a surveillance system in place around the world that is very factive.". ... -Melfort Journal



Oscient Pharmaceuticals Reports Financial Results for First ...  May 9, 2006
In the first quarter of 2006, $9.2 million in revenue was generated from the Company's lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, FDA-approved ... - Genetic Engineering News

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Apr 20, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News

Completion of ANA380 Dosing in Phase II Clinical Trial Confirms ...  Apr 26, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PharmaLive.com





Singapore's biotech pipeline show promise  11 Apr 2006
South Korea had its own success story recently with the antibiotic Factive, the first Korean-developed compound to be approved for marketing in the United ... - Reuters

Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster ...  Apr 4, 2006
Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, is the subject of two poster presentations at ... - International News Service

Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster ...  Apr 4, 2006
NICE, France--(BUSINESS WIRE)--April 4, 2006--Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, is ... - Business Wire

Oscient Pharmaceuticals Announces $35 Million Private Placement ...  Apr 6, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News

Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce ...  Mar 12, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional